Cancer最新文献

{"title":"Progression-free survival and overall survival in the first-line treatment of BRCA wild-type advanced epithelial ovarian cancer: An analysis of patient-level data pooled from historical clinical trials","authors":"Le Su MD, PhD,&nbsp;Mehmet Burcu PhD, FISPE,&nbsp;Kayleen Ports MS,&nbsp;Vlad Gradinariu MS,&nbsp;Yahav Itzkovich BA,&nbsp;Rahul Jain PhD,&nbsp;Karin Yamada MD,&nbsp;Cumhur Tekin MD,&nbsp;Lei Chen PhD","doi":"10.1002/cncr.70630","DOIUrl":"10.1002/cncr.70630","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Progression-free survival (PFS) is a common primary endpoint in first-line epithelial ovarian cancer (EOC) trials; however, its relationship with overall survival (OS) remains uncertain. The patient-level PFS-OS association among individuals with BRCA wild-type advanced EOC treated with first-line platinum-based chemotherapy was evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective analysis pooled patient-level data from first-line advanced EOC historical trials sourced from the Medidata Enterprise Data Store. Eligible patients had BRCA wild-type disease and initiated platinum-based chemotherapy (index date) after primary debulking surgery or as neoadjuvant therapy before planned interval debulking surgery. The PFS-OS association was evaluated using Spearman's correlation (ρ) and landmark analyses at prespecified timepoints (9, 12, 15, and 18 months after index).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 487 patients (50.1% aged ≥65 years; 90.1% White; 63.7% International Federation of Gynecology and Obstetrics stage III; 54.6% ECOG-PS 0; 37.3% primary debulking surgery; 53.0% interval debulking surgery; median follow-up 3.4 years), the median PFS and OS were 15.6 months (95% CI, 13.8–16.8) and 42.1 months (95% CI, 37.8–45.7), respectively. The PFS-OS correlation (ρ) was 0.7 (95% CI, 0.6–0.8). Across all landmarks, progression-free patients experienced longer subsequent OS; at 15 months, the unadjusted HR was 0.29 (95% CI, 0.22–0.37). Associations remained after covariate adjustment and did not vary by best overall response, bevacizumab use, or surgical type/outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this patient population, PFS demonstrated a consistently moderate, positive association with OS across multiple analytical approaches. These findings provide patient-level evidence that PFS is an informative early endpoint, although additional trial-level evaluations are needed to confirm PFS as a validated surrogate for OS in first-line EOC.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149072758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current challenges and emerging therapeutic strategies in lung cancer care: Insights from Bridging the Gaps 2025","authors":"Narjust Florez MD,&nbsp;Sandip Pravin Patel MD,&nbsp;Ravi Salgia MD, PhD,&nbsp;Jacob Sands MD,&nbsp;Erin L. Schenk MD, PhD,&nbsp;Elaine Shum MD,&nbsp;Mihaela Aldea MD, PhD,&nbsp;Christine M. Bestvina MD,&nbsp;Jessica Donington MD, MSCR,&nbsp;Christine A. Garcia MD, MPH,&nbsp;Jorge Nieva MD,&nbsp;David R. Gandara MD,&nbsp;Balazs Halmos MD, MS,&nbsp;Fred R. Hirsch MD, PhD,&nbsp;Xiuning Le MD, PhD,&nbsp;Percy Lee MD,&nbsp;Jyoti Malhotra MD, MPH,&nbsp;Tejas Patil MD,&nbsp;Solange Peters MD, PhD,&nbsp;Jonathan Wesley Riess MD, MS,&nbsp;Julia Rotow MD,&nbsp;Fawzi Abu Rous MD,&nbsp;Joshua Sabari MD,&nbsp;Triparna Sen PhD, MS,&nbsp;Eric K. Singhi MD,&nbsp;Ana I. Velázquez MD, MSc,&nbsp;Heather A. Wakelee MD,&nbsp;Edward S. Kim MD, MBA","doi":"10.1002/cncr.70633","DOIUrl":"10.1002/cncr.70633","url":null,"abstract":"<div>\u0000 \u0000 <p>Recent years have seen substantial advances in lung cancer management, with therapeutic options expanding rapidly through the integration of targeted therapies, immunotherapies, antibody–drug conjugates, and novel, immune-engaging agents. Although outcomes have improved for selected patients with non–small cell lung cancer and small cell lung cancer, the increasing number of regimens has amplified clinical complexity, with persistent evidence gaps, limited head-to-head comparisons, and underrepresentation of key subgroups in trials. Emerging genomic tools and novel therapeutic modalities provide opportunities to further improve patient outcomes but also add to the challenges of clinical decision-making. To address these issues, a multidisciplinary panel of oncology experts, primarily based in the United States, convened to review current evidence gaps, controversies, and unmet needs in the management of lung cancer. Key areas were identified in treatment selection and sequencing as well as the management of high-risk subtypes, highlighting the need for prospective, head-to-head clinical trials. Findings from this panel will inform a 2026 follow-up conference in which a modified Delphi method will be used to develop formal consensus recommendations to provide actionable guidance for practicing clinicians.</p>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70633","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149072942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in sociodemographic factors associated with human papillomavirus vaccine hesitancy in the United States: 2010–2022","authors":"Dina K. Abouelella BDS, MPH, CPH,&nbsp;Mrudula Nair BDS, MPH,&nbsp;Mary A. Gerend PhD,&nbsp;Olivia Aspiras PhD,&nbsp;Nosayaba Osazuwa-Peters BDS, PhD, MPH, CHES,&nbsp;Eric Adjei Boakye PhD","doi":"10.1002/cncr.70636","DOIUrl":"10.1002/cncr.70636","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Previous studies suggest that rates of human papillomavirus (HPV) vaccine hesitancy vary by adolescent and parent sociodemographic characteristics. This study assessed trends in the characteristics of parents who did not intend to have their child vaccinated for HPV in the United States.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors used data from the 2010–2022 National Immunization Survey–Teen among adolescents who had received zero doses of the HPV vaccine. Vaccine hesitancy was assessed with the question “How likely is it that your teen will receive HPV shots in the next 12 months?” Parents who responded with “not too likely, “not likely at all,” or “not sure/don't know” were deemed vaccine hesitant. Joinpoint regression estimated yearly increases and/or decreases in vaccine hesitancy by adolescent and mother characteristics through annual percent changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 204,196 unvaccinated adolescents were included in the study, 66.0% had parents who were classified as HPV vaccine hesitant. Overall, the proportion of adolescents with mothers who were HPV vaccine hesitant declined from 72% in 2010 to 61% in 2022. Among parents with female children, HPV vaccine hesitancy decreased significantly from 2010 to 2012, increased significantly from 2012 to 2018 followed by a significant decrease from 2018 to 2022. Among parents with male children, HPV vaccine hesitancy decreased significantly from 2010 to 2012 and remained stable from 2012 to 2022. Parents with children of all racial and ethnic groups experienced significant decreases in HPV vaccine hesitancy from 2010 to 2012 and then remained stable from 2012 to 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This study emphasizes the need to dispel misconceptions and create awareness about HPV vaccine across all strata of the society.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13619007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149072852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial","authors":"Soumyajit Roy MBBS, MSc,&nbsp;Andrew J. Armstrong MD, MSc,&nbsp;Neeraj Agarwal MD,&nbsp;Rana R. McKay MD,&nbsp;Angela Y. Jia MD, PhD,&nbsp;Samuel Lichtman-Mikol BS,&nbsp;Pedro C. Barata MD, MSc,&nbsp;Jorge A. Garcia MD,&nbsp;Jason R. Brown MD, PhD,&nbsp;Yashasvi Mumgandi BS,&nbsp;Spyridon P. Basourakos MD,&nbsp;Iris Y. Sheng MD,&nbsp;Amar U. Kishan MD,&nbsp;Nicholas G. Zaorsky MD, MS,&nbsp;Jonathan E. Shoag MD,&nbsp;Scott C. Morgan MD, MSc,&nbsp;Christopher J. D. Wallis MD, PhD,&nbsp;Yilun Sun PhD,&nbsp;Eric J. Small MD,&nbsp;Fred Saad MD,&nbsp;Neal D. Shore MD,&nbsp;Daniel E. Spratt MD","doi":"10.1002/cncr.70615","DOIUrl":"https://doi.org/10.1002/cncr.70615","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Early favorable prostate-specific antigen (PSA) response to ≤0.2 ng/mL by 6 months is associated with superior overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). The nadir androgen receptor pathway inhibitor (ARPI)-derived integrative response (NADIR) model is a multivariable model developed to predict this early favorable PSA response in patients receiving ARPI. The authors report an independent external validation of the locked NADIR model in the ARCHES trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Of 574 enzalutamide-treated patients, 558 with complete predictors were included. Discrimination, Brier score/index of prediction accuracy (IPA), and calibration were assessed. Predicted probability tertiles were used descriptively for PSA response. Six-month landmark Cox models explored associations with OS. A sensitivity analysis restricted the cohort to &lt;3 months of prior androgen deprivation therapy (ADT).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Early favorable PSA response occurred in 359 patients (64%). The area under the receiver operating characteristic curve was 0.80 (95% confidence interval [CI], 0.76–0.83), the Brier score was 0.17, and the IPA was 25%. Recalibration intercept was 0.026 and slope was 0.97. Response rates across decreasing predicted probability tertiles were 92%, 64%, and 37%. In the landmark analysis (<i>n</i> = 547; 177 deaths), each 10-percentage-point increase in predicted probability was associated with lower mortality (hazard ratio, 0.90; 95% CI, 0.85–0.96). In the &lt;3-month prior-ADT subgroup (<i>n</i> = 401), the area under the receiver operating characteristic curve and IPA were 0.78 and 23%, respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The NADIR model demonstrates robust and reproducible discrimination, calibration, and prognostic stratification in a distinct ARPI-treated mHSPC cohort, supporting its potential utility for early response risk stratification and trial enrichment pending prospective validation of model-guided treatment adaptation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149048579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progression-free survival and objective response rate as a surrogate end point for overall survival in metastatic renal cell carcinoma: A systematic review and meta-analysis","authors":"Russell Leong BHSc,&nbsp;David Chen MD,&nbsp;Laith Almasri BSc,&nbsp;Nicholas Lum BHSc,&nbsp;Karren Xiao BHSc,&nbsp;Maryam Soleimani MD,&nbsp;Christian K. Kollmannsberger MD,&nbsp;Srinivas Raman MD, MASc","doi":"10.1002/cncr.70616","DOIUrl":"10.1002/cncr.70616","url":null,"abstract":"<p>The objective of this systematic review and meta-analysis was to evaluate the validity of progression-free survival (PFS) and the objective response rate (ORR) as surrogate end points for overall survival (OS) in randomized controlled trials (RCTs) of metastatic renal cell carcinoma. The MEDLINE, Embase, and Cochrane CENTRAL databases were searched from inception to June 10, 2025. Associations between treatment effects on OS, PFS, and ORR were assessed using Pearson correlation coefficients (<i>r</i>). Surrogate threshold effect (STE) analyses determined the minimum PFS hazard ratio (HR) or ORR odds ratio (OR) required to predict OS benefit. Subgroup analyses were conducted by treatment class, line of therapy, and histology. Sixty-two randomized controlled trials comprising 24,518 patients were included. PFS-OS demonstrated a moderate correlation (<i>r</i> = 0.52; 95% confidence interval [CI], 0.38–0.66), with an STE (HR, 0.92; 95% CI, 0.79–1.09). ORR-OS demonstrated a moderate correlation (<i>r</i> = −0.59; 95% CI, −0.72, −0.45), with an STE (OR, 1.40; 95% CI, 0.99–1.89). Subgroup estimates varied across treatment settings and were frequently imprecise, particularly for ORR and in smaller treatment-class subgroups; limited representation of non–clear cell renal cell carcinoma precluded reliable histology-specific conclusions. Overall, PFS and ORR had moderate trial-level associations with OS in metastatic renal cell carcinoma, but the overall analyses did not demonstrate sufficiently consistent surrogacy to reliably predict OS benefit. These findings should be interpreted cautiously given the substantial heterogeneity of the included trials. Surrogate validity appears to be context-dependent, supporting continued reliance on OS and the need for more robust surrogate end points.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70616","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward a globally integrated histologic risk classification of pretreated Wilms tumor","authors":"Filippo Spreafico MD,&nbsp;Arnauld Verschuur MD","doi":"10.1002/cncr.70623","DOIUrl":"10.1002/cncr.70623","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome after first relapse post-immunochemotherapy in older adults with Philadelphia-negative B-cell acute lymphoblastic leukemia: A GRAALL study","authors":"Perrine Moyer MD,&nbsp;Thibaut Leguay MD,&nbsp;Maxime Jullien MD, PhD,&nbsp;Françoise Huguet MD,&nbsp;Gabrielle Roth-Guepin MD,&nbsp;Yosr Hicheri MD,&nbsp;Amine Belhabri MD,&nbsp;Thomas Cluzeau MD, PhD,&nbsp;Ana Berceanu MD,&nbsp;Emmanuelle Tavernier MD,&nbsp;Stéphane Leprêtre MD,&nbsp;Karin Bilger MD,&nbsp;Pascal Turlure MD,&nbsp;Jean-Noel Bastié MD, PhD,&nbsp;Marie Balsat MD,&nbsp;Magda Alexis MD,&nbsp;Eolia Brissot MD, PhD,&nbsp;Delphine Lebon MD,&nbsp;Emmanuel Raffoux MD,&nbsp;Stefan Wickenhauser MD,&nbsp;Victoria Cacheux MD,&nbsp;Anne Banos MD,&nbsp;Sarah Bonnet MD,&nbsp;Nicolas Boissel MD, PhD,&nbsp;Hervé Dombret MD,&nbsp;Philippe Rousselot MD, PhD,&nbsp;Patrice Chevallier MD, PhD","doi":"10.1002/cncr.70621","DOIUrl":"10.1002/cncr.70621","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Inotuzumab (InO)-based frontline regimens have significantly improved the survival of older patients with Philadelphia-negative (Ph–) B-cell acute lymphoblastic leukemia (B-ALL). Yet, outcome after relapse is not reported for this population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The retrospective RELAPSINO study describes post-relapse outcome of 48 older patients treated front-line with a combination of InO and low-dose chemotherapy in the EWALL-INO trial (NCT03249870). At relapse (91% medullary), median age was 70 years and median duration of first complete remission (CR1) 15.2 months. CD19 or CD22 expression loss was observed in respectively 13% and 23% of evaluable cases. Most patients (85%) received salvage therapy (blinatumomab, low dose or intensive chemotherapy, in combination or not). There was no InO re-treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall, CR2 was reached by 51% of the patients. Median event-free survivals (EFS, 3.2 months) and overall survivals (OS, 4.5 months) were dismal. For patients achieving CR2, 2-year OS was 46% and leukemia-free survival (LFS) was 36%. By multivariable analysis, not receiving intensive chemotherapy was associated with significantly lower EFS (hazard ratio [HR], 3.28; 95% confidence interval [CI], 1.43–7.53, <i>p</i> = .005), LFS (HR, 13.2; 95% CI, 2.46–70.88, <i>p</i> = .003), and OS (HR, 3.25; 95% CI, 1.39–7.59, <i>p</i> = .006). CR1 duration ≥12 months was significantly associated with better EFS (HR, 0.31; 95% CI, 0.14–0.67, <i>p</i> = .003), LFS (HR, 0.16; 95% CI, 0.04–0.72, <i>p</i> = .01), and OS (HR, 0.42; 95% CI, 0.20–0.89, <i>p</i> = .023). Not achieving CR2 was associated with lower OS (HR, 8.0; 95% CI, 3.25–20.1, <i>p</i> &lt; .001). Receiving blinatumomab had no impact.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These results indicate that salvage regimen should be proposed in this context, allowing 50% of patients to achieve CR2 and have better survival.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis","authors":"Hira Mian MD, MSc,&nbsp;Muhammad Salman Faisal MD,&nbsp;Tiening Chen MS,&nbsp;Ruta Brazauskas PhD,&nbsp;Temitope Oloyede MS,&nbsp;Nausheen Ahmed MD,&nbsp;Aimaz Afrough MD,&nbsp;Larry D. Anderson MD, PhD,&nbsp;Rahul Banerjee MD, FACP,&nbsp;Jesus Berdeja MD,&nbsp;Aram Bidikian MD,&nbsp;Jakob Devos BS,&nbsp;Binod Dhakal MD,&nbsp;Ajoy Dias MD,&nbsp;Danai Dima MD,&nbsp;Yvonne A. Efebera MD, MS,&nbsp;Lohith Gowda MD,&nbsp;Doris K. Hansen MD,&nbsp;Hamza Hashmi MD,&nbsp;Heather J. Landau MD,&nbsp;Lazaros Lekakis MD,&nbsp;Abu-Sayeef Mirza MD, MPH,&nbsp;Ravi Narra MS,&nbsp;Krina Patel MD, MSc,&nbsp;Ashley E. Rosko MD,&nbsp;Mark Schroeder MD,&nbsp;Surbhi Sidana MD,&nbsp;Saad Usmani MD, FACP,&nbsp;Marcelo C. Pasquini MD, MS,&nbsp;Taiga Nishihori MD,&nbsp;Othman Salim Akhtar MD,&nbsp;Meera Mohan MD, MS","doi":"10.1002/cncr.70614","DOIUrl":"10.1002/cncr.70614","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ciltacabtagene autoleucel (cilta-cel), an anti–B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using the Center for International Blood and Marrow Transplant Research registry, this study evaluated outcomes of frail patients receiving commercial cilta-cel from March 2022 to December 2023. Frailty was defined by an adapted simplified score incorporating age, performance status, and comorbidities.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 541 patients with available frailty status, 183 (33.8%) were frail and 358 (66.2%) were nonfrail. Overall response rates were comparable (frail 82.8% vs. nonfrail 88.5%). However, frail patients had inferior progression-free survival (PFS) (12-month PFS, 62.7% [95% confidence interval (CI), 53.6%–71.3%] vs. 75.9% [95% CI, 70.4%–81.1%]; <i>p</i> &lt; .01) and overall survival (OS) (12-month OS 72.8% [95% CI, 64.9%–80.0%] vs. 90.4% [95% CI, 86.6%–93.7%]; <i>p</i> &lt; .01). Twelve-month treatment-related mortality in frail patients was 6.8% (95% CI, 3.4%–11.2%) versus 3.6% (95% CI, 1.8%–6.1%), <i>p</i> = .12. Cytokine release syndrome (grade ≥2) occurred in 22.4% of frail versus 17.9% of nonfrail patients (<i>p</i> = .05), and immune effector cell–associated neurotoxicity (ICANS) of any grade was reported in 32.2% versus 17.6% (<i>p</i> &lt; .01). Rates of cranial nerve palsies and Parkinsonism were comparable. Prolonged cytopenia (&gt;day 30) was more common in frail patients (30.6% vs. 21.2%; <i>p</i> &lt; .01). On multivariable analysis, frailty independently predicted worse PFS (hazard ratio [HR], 1.67; 95% CI, 1.16–2.40), OS (HR, 2.46; 95% CI, 1.57–3.87), and higher odds of any-grade ICANS (odds ratio, 2.01; 95% CI, 1.32–3.08) (all <i>p</i> &lt; .01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Cilta-cel remains effective in frail RRMM, but frailty is associated with reduced survival and increased toxicity, supporting tailored CAR-T strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70614","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations of the American Cancer Society workshop on design, conduct, analysis, and reporting of multicancer early detection trials with late-stage incidence end points and post-trial ongoing evaluation—The Peachtree Consensus","authors":"Ruth Etzioni PhD,&nbsp;Larry Kessler ScD,&nbsp;Deb Schrag MD, MPH,&nbsp;Peter Sasieni PhD,&nbsp;Hilary A. Robbins PhD,&nbsp;Hormuzd A. Katki PhD,&nbsp;Stephen W. Duffy PhD,&nbsp;Roman Gulati MS,&nbsp;Diana Buist PhD,&nbsp;Sean Tunis MD, MSc,&nbsp;Rebecca Landy PhD,&nbsp;Jane Lange PhD,&nbsp;Alpa V. Patel PhD,&nbsp;William L. Dahut MD,&nbsp;Robert A. Smith PhD","doi":"10.1002/cncr.70628","DOIUrl":"10.1002/cncr.70628","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In a new era of multicancer early detection (MCED), late-stage incidence has been proposed as an end point for the evaluation of test efficacy, marking a departure from the established end point of cancer mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The American Cancer Society convened a panel of 15 academic researchers with expertise in cancer screening evaluation to develop principles assuring the validity and interpretability of MCED trials with late-stage incidence end points and advancing implementation of tests with potential for meaningful clinical utility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The definition of late-stage cancer is critical and affects study design, interpretation, and outcomes. The authors of the Peachtree Consensus recommend considering cancer-type–specific definitions of late stage and paying attention to comparability of staging intensity in both trial arms. The duration of screening and the follow-up interval after the last screen should be chosen based on the preclinical early stage and late-stage durations of the target cancer types. The authors also recommend reporting aggregate results and results for individual cancer types as numbers permit and summarizing relative and absolute benefits. Predicted mortality reductions should be calculated to contextualize a late-stage result and the inputs and assumptions involved should be reported. Given a significant late-stage reduction suggestive of meaningful clinical benefit, the authors support launching consortium and demonstration studies while continuing to track trial mortality outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Trials with late-stage incidence end points that are conducted using these principles should support the development of evidence-based screening guidelines as well as the creation of accessible data resources for observational and modeling studies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13599050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149023346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Annual Report to the Nation on the Status of Cancer, featuring 21st century progress against lung cancer","authors":"S. Jane Henley MSPH,&nbsp;David A. Siegel MD, MPH,&nbsp;Albert U. Firth BS,&nbsp;Rebecca L. Siegel MPH,&nbsp;Recinda L. Sherman MPH, PhD, ODS-C,&nbsp;Serban Negoita MD, DrPH,&nbsp;Farhad Islami MD, PhD,&nbsp;Hyuna Sung PhD,&nbsp;Brandy Peaker MD, MPH,&nbsp;Robert N. Anderson PhD,&nbsp;Ahmedin Jemal DVM, PhD,&nbsp;Kathleen A. Cronin PhD, MPH,&nbsp;Karen L. Knight MS","doi":"10.1002/cncr.70577","DOIUrl":"10.1002/cncr.70577","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This annual report represents a collaborative effort by leading cancer surveillance organizations to present reliable, comprehensive US statistics on cancer incidence and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Cancer incidence data were obtained from population-based cancer registries funded by the Centers for Disease Control and Prevention and/or the National Cancer Institute and compiled by the North American Association of Central Cancer Registries. Cancer death data were obtained from the National Center for Health Statistics’ National Vital Statistics System. Age-standardized rates (per 100,000) and average annual changes in rates calculated with joinpoint regression are reported by cancer type, sex, race and ethnicity, and age. Lung cancer risk factors and outcomes during 2000–2025 were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Overall cancer incidence rates were 504.6 among males and 443.0 among females during 2018–2019/2021–2022. Excluding 2020, cancer incidence rates were stable among males (2013–2022) and increased 0.4% per year among females (2011–2022). Lung cancer incidence decreased 3.5% among males and 1.9% among females per year during 2018–2022. During 2019–2023, overall cancer death rates were 171.5 among males and 126.3 among females, decreasing 1.6% per year among males and 1.1% among females. During this period, lung cancer death rates decreased 4.7% per year among males and 3.0% among females. Since the early 2000s, smoking fell by one half, early diagnosis of lung cancer increased by two thirds, and 5-year relative survival for lung cancer doubled.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Cancer incidence was stable among males but increased slowly among females. Cancer mortality continued to decline, largely because of sustained progress against lung cancer.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 19","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70577","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149014988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}